REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 30449 participants.
Also called NCT01252953
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 30,449 participants
- Registry
-
NCT01252953 -
2010-023467-18
-
- Main results
- Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- Other papers using this trial's data
- Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States
- Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT01252953. Randomized; quadruple masking; primary purpose prevention. Start 2011-06 (registry gives no type); primary completion 2017-01-31 (actual). Results posted on 2018-05-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
- Acronym
- REVEAL
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Anacetrapib
- Intervention (Drug)
- Placebo anacetrapib
- Lead sponsor
- University of Oxford
- Collaborator
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01252953- Content hash
d5b6eede96b7c5ace3409700417f10939e0cd823b06e7367c167ca7da21407f1